Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases
Article
[키워드] acute respiratory syndrome
Administered
Anti-RBD IgG
antibody
Antibody Response
approval
baseline
biologic
BNT162b2 mRNA
BNT162b2 mRNA vaccine
children
Cohort
cohort of patient
Combined therapy
coronavirus
coronavirus disease
COVID-19
disease
Disease activity
domain
dose
dose regimen
effective
elevated
evaluated
humoral
Humoral response
IgG antibody
immunogenicity
immunomodulatory
IQR
Local
median
mRNA vaccine
of BNT162b2
paediatric rheumatic disease.
pandemic
Patient
RBD
receiving
rheumatic disease
safety profile
SARS-CoV-2
second dose
significantly lower
Spike protein
study period
systemic side effect
titre
treated
Treatment
Vaccine
were measured
[DOI] 10.1093/rheumatology/keac140 PMC 바로가기
[DOI] 10.1093/rheumatology/keac140 PMC 바로가기